Sign In
Buy IBRX
$7.18
-0.0500 (-0.692%)
At Close: Jun 03, 2026
KLP Kapitalforvaltning AS Cuts Holdings in ImmunityBio, Inc. $IBRX
03:02am, Wednesday, 22'nd Oct 2025
KLP Kapitalforvaltning AS lessened its stake in ImmunityBio, Inc. (NASDAQ: IBRX) by 41.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange
ImmunityBio: A Small Bet Is Warranted
01:24pm, Friday, 03'rd Oct 2025
ImmunityBio should be rated as a speculative buy for aggressive investors only, offering significant upside despite ongoing dilution and cash burn concerns. Anktiva, IBRX's lead therapy, is ramping up
Biotech Breakouts: 3 Stocks With Massive Upside Potential
06:23pm, Wednesday, 17'th Sep 2025
Investing in biotechnology stocks is complex due to the science behind the company's drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves i
ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking
12:26pm, Thursday, 11'th Sep 2025
I maintain a Hold rating on ImmunityBio as Anktiva shows strong NMIBC data but the commercial uptake remains slow and uncertain. IBRX's Q2 revenues rose to $26.4M, but accumulated losses and lack of f
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced new paradigm changing findings from the Phase 2 QUILT-3.055 study, demonstratin
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced early findings from the first five recurrent glioblastoma patients treated with
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
08:30am, Tuesday, 19'th Aug 2025
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the opening of a new Phase 2 study to assess the BioShield™ platform, anchore
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today early findings from its QUILT-106 Phase I trial, showing highly promising complete re
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the Michael E. DeBakey Department of Veterans Affairs (VA) Medical Center in Ho
IBRX Sales Soar 2,540%
11:55pm, Tuesday, 05'th Aug 2025
ImmunityBio (IBRX -0.21%), a commercial-stage biotechnology company, released its second-quarter results on August 5, 2025. The main headline: revenue (GAAP) jumped to $26.4 million, soundly beating a
ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates
09:20am, Tuesday, 05'th Aug 2025
ImmunityBio (IBRX) came out with a quarterly loss of $0.1 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.2 per share a year ago.
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced its financial results for the fiscal quarter and six months ended June 30, 2025
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
06:03am, Friday, 25'th Jul 2025
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide further working capital and support i
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced preliminary financial results for the fiscal quarter ended June 30, 2025, and c
ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval
10:45am, Monday, 21'st Jul 2025
Recent ASCO data and UK MHRA approval for ANKTIVA reinforce my bullish thesis, despite the FDA's Refusal to File setback. ANKTIVA's potential to reverse lymphopenia in late-stage cancer patients could
